$97 Million

Adaptimmune Therapeutics plc

Follow-on Offering

Sole Bookrunner, January 2020

Adaptimmune Therapeutics plc
Adaptimmune Therapeutics is a clinical stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors.